FHTX Stock Analysis: Buy, Sell, or Hold?
FHTX - Foghorn Therapeutics Inc. Common Stock
$3.79
-0.25 (-6.19%)
▼
5d:
-14.64%
30d:
-22.02%
90d:
-31.71%
WAIT
LOW Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When FHTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: FHTX is down 14.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: FHTX is down 14.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: FHTX is currently trading at $3.79, which is considered oversold relative to its 30-day fair value range of $4.32 to $5.19.
Technical Outlook: Technically, FHTX is in a downtrend. The price is currently testing key support at $3.84. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.44 (+202.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, FHTX is in a downtrend. The price is currently testing key support at $3.84. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.44 (+202.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.32 -
$5.19
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.2%)
- BULLISH: Trading 202.0% below Wall St target ($11.44)
- WARNING: Recommendation downgraded due to -14.6% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$4.32 -
$5.19
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.84
Resistance Level
$4.87
Current Trend
Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.08
Wall Street Target
$11.44
(+202.0%)
Revenue Growth (YoY)
-45.1%
Profit Margin
-266.9%
Share & Embed Analysis
Last updated: May 18, 2026 9:06 AM ET
Data refreshes hourly during market hours. Next update: 10:06 AM
Data refreshes hourly during market hours. Next update: 10:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FHTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 53 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 51 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 61 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 58 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$126 | 48 HOLD |
